Keywords: Biomarkers, Neurodegeneration
Motivation: Robust methods are urgently needed for preclinical evaluation of novel Alzheimer Disease (AD) therapies to accelerate drug discovery. MRI methods hold significant promise, with quantitative Gradient Recalled Echo (qGRE) shown to provide insight into neurodegeneration in AD prior to atrophy development in humans.
Goal(s): In this study a novel method is shown to non-invasively measure the longitudinal neuronal loss in the hippocampus of a mouse model of AD.
Approach: Histological validation of the findings is performed.
Results: A strong correlation is revealed between the MRI metric and myelin content, hence offering the explanation for the mechanism of observed contrast.
Impact: A robust method for longitudinal in-vivo quantification of neuronal density loss in a mouse model of AD is presented and validated, allowing for efficient preclinical evaluation of novel AD therapeutics and accelerated drug development in the field.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords